Three years after Michael Davidson and his colleagues sold the omega-3 drug Epanova to AstraZeneca ($AZN) in the $443 million Omthera buyout, the biotech exec has rounded up some fresh support from a seasoned ally in the venture world to begin building a new biotech focused on cardiovascular disease.